Cost-effective prescribing: Trying to hit the target in Ontario and Australia

Australian Prescriber

Volumn 25, Issue 6, 2002, Pages 128-130

  O'Brien, Bernie J ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Cost of drugs; Pharmaceutical Benefits Scheme

Indexed keywords

ALENDRONIC ACID; AMFEBUTAMONE; AMLODIPINE; ATORVASTATIN; CELECOXIB; DILTIAZEM; ENALAPRIL; ETIDRONIC ACID; FLUTICASONE PROPIONATE; INSULIN; MISOPROSTOL; OLANZAPINE; OMEPRAZOLE; PRAVASTATIN; RANITIDINE; ROFECOXIB; SERTRALINE; SIMVASTATIN;

AUSTRALIA; CANADA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; GASTROINTESTINAL HEMORRHAGE; GOVERNMENT; HEALTH INSURANCE; HUMAN; PRESCRIPTION; SHORT SURVEY; SIDE EFFECT;

EID: 0036919387     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2002.125     Document Type: Short Survey

References (4)

1. Top 10 drugs. Aust Prescr 2001;24:136.
2. The 2000/1 Report Card for ODBP Including Detailed Statistics http://www.gov.on.ca/MOH/english/pub/ministry/odb_report01/drug_rep.html.
3. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health and Long-term Care; 1994.
4. Laupacis A. Inclusion of drugs in provincial drug benefit programs: Who is making these decisions, and are they the right ones? CMAJ 2002; 166:44-7.